Neurosurgery in a patient with severe hemophilia B: an experience using eftrenonacog alfa as perioperative management

Olga Benitez Hidalgo; M Fernanda Martinez Garcia; Agustin Bescos Cabestre; Juan Carlos Juarez Gimenez; Mercedes Gironella Mesa; Francesc Bosch Albareda

doi:10.1002/ccr3.5848

Neurosurgery in a patient with severe hemophilia B: an experience using eftrenonacog alfa as perioperative management

Clin Case Rep. 2022 May 23;10(5):e05848. doi: 10.1002/ccr3.5848. eCollection 2022 May.

Authors

Olga Benitez Hidalgo^{1

2}, M Fernanda Martinez Garcia^{1

2}, Agustin Bescos Cabestre³, Juan Carlos Juarez Gimenez⁴, Mercedes Gironella Mesa^{1

2}, Francesc Bosch Albareda^{1

2}

Affiliations

¹ Hematology Department Experimental Hematology Vall d'Hebron Institute of Oncology (VHIO) Hospital Universitari Vall d'Hebron Vall d'Hebron Barcelona Hospital Campus Barcelona Spain.
² Medicine Department Universitat Autònoma de Barcelona Barcelona Spain.
³ Neurosurgery Department- Spine Unit Hospital Universitari Vall d'Hebron Barcelona Spain.
⁴ Hospital Pharmacy Department Hospital Universitari Vall d'Hebron Barcelona Spain.

Abstract

Extended half-life FIX (EHL-FIX) concentrates have been developed with the purpose of reducing the frequency of infusions in patients with severe or moderate hemophilia B. We describe the case of a 63-year-old patient with severe hemophilia B (sHB) treated with FIX-Fc fusion protein (rFIXFc) who underwent neurosurgery.

Keywords: anesthesia; haemophilia B; hematology; neuosurgery; pharmacology; rFIX‐Fc.

Publication types

Case Reports